No association between hOGG1 Ser326Cys polymorphism and hepatocellular carcinoma.
To clarify any association between the hOGG1 Ser326Cys polymorphism and susceptibility to hepatocellular carcinoma (HCC). The PubMed, CNKI databases were searched for all available articles. The OR corresponding to the 95% confidence interval (95% CI) was used to assess the association between hOGG1 Ser326Cys polymorphism and susceptibility to HCC. Seven case-control studies, with 1,663 cases and 1,675 controls, were available for this analysis. No association was found between hOGG1 Ser326Cys polymorphism and HCC risk (dominant model: OR=0.695, 95% CI: 0.501-0.964, p=0.029; additive model: OR=0.682, 95% CI: 0.374-1.245, p=0.213; recessive model: OR=1.215, 95% CI: 0.711-2.078, p=0.476). Sensitivity analysis did not perturb the results. These findings indicated that hOGG1 Ser326Cys polymorphism may not play a role in HCC development. However, larger scale studies are needed for confirmation.